UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022
Commission File Number: 001-40277
OLINK HOLDING
AB (PUBL)
(Exact Name of Registrant as Specified in its Charter)
Uppsala Science Park
SE-751 83
Uppsala, Sweden
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
On June 1, 2022, Olink Holding AB (publ) issued a news release, which is furnished as Exhibit 99.1 to this Form 6-K.
| Exhibit No. | Description |
| 99.1 | Olink Holding AB (publ) news release dated June 1, 2022. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OLINK HOLDING AB (PUBL) | ||
| By: | /s/ Jon Heimer | |
| Name: | Jon Heimer | |
| Title: | Chief Executive Officer | |
Date: June 1, 2022
Exhibit 99.1
Olink to participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
UPPSALA, Sweden, June 1, 2022 -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced its participation in the 43rd Annual Goldman Sachs Global Healthcare Conference.
Company management will participate in a fireside chat on Tuesday, June 14th, 2022, at 2:00 pm PT / 5:00 pm ET.
A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at https://investors.olink.com/investor-relations.
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
Investor Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com